Press Releases

In a strategic move to enhance its manufacturing capabilities, a major pharmaceutical company has announced its partnership with a leading Contract Manufacturing Organization (CMO). This collaboration is aimed at expanding the production capacity for the company’s pipeline of innovative therapies, which are currently in various stages of clinical development.The partnership will enable the pharmaceutical company to leverage the CMO's advanced manufacturing facilities and expertise in

In a significant advancement for laboratory operations, a pioneering biotech firm has introduced a range of innovative lab automation solutions designed specifically for drug development. This new technology aims to enhance efficiency, reduce human error, and accelerate the overall drug discovery process.The newly launched automation systems integrate state-of-the-art robotics and artificial intelligence to optimize various aspects of drug development, from high-throughput screening to

Roche announced today that it has received the EU CE mark for its Port Delivery Platform containing Susvimo, which will now be known as Contivue® in the EU.6 The device comprises the eye implant through which Susvimo is delivered, and four ancillary devices to initially fill, insert, refill, and remove the implant (if required).6 Susvimo® (ranibizumab injection) 100 mg/mL is currently under review with the European Medicines Agency (EMA) for the treatment of nAMD.6 With immediate and

Zydus Lifesciences Ltd., a global innovation-driven healthcare company, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.

UltraClean Technologies has unveiled its latest range of cleanroom solutions, specifically designed to cater to the pharmaceutical industry's evolving needs amid heightened regulatory scrutiny. These new offerings come as part of UltraClean's commitment to providing cutting-edge technologies that support manufacturers in achieving compliance with stringent cleanliness and safety standards.Recognizing the significance of compliant cleanroom environments, UltraClean has integrated advanc

In a significant move for the pharmaceutical research landscape, BioPharmaTech has partnered with Genomics Asia, aiming to enhance drug discovery and development through cutting-edge genomic technologies. This collaboration seeks to leverage Genomics Asia's powerful sequencing capabilities and BioPharmaTech's advanced drug formulation expertise to streamline the identification of potential therapeutics.The partnership will utilize artificial intelligence (AI) and machine learning algor

On September 5, 2025, two renowned biotechnology companies announced a strategic partnership aimed at enhancing their research and development (R&D) capabilities, particularly in the area of novel drug discovery. This collaboration is set to facilitate the sharing of resources, technology advancements, and expert knowledge, ultimately accelerating the development of groundbreaking therapeutic solutions for unmet medical needs.The partnership signifies a shared vision to drive innovatio

On September 5, 2025, a leading pharmaceutical provider announced the launch of its innovative cold chain storage solutions, designed to enhance the integrity and safety of temperature-sensitive pharmaceutical products during distribution across Asia. With an emphasis on compliance and efficiency, the company revealed its state-of-the-art packaging and logistics systems that leverage real-time monitoring and automated temperature control technologies.This launch comes in response to th

Achieve Life Sciences, Inc. a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence, today announced that the U.S. Food and Drug Administration (FDA) has accepted the cytisinicline New Drug Application (NDA) for a new treatment for smoking cessation in adults. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) targeted action date of June 20, 2026. “The FDA&rsquo

Advanced Pharmaceutical Manufacturing (APM), an emerging leader in drug production technologies, has announced the establishment of a new state-of-the-art manufacturing facility in Singapore. This cutting-edge facility is set to transform the local pharmaceutical landscape by significantly increasing production capacity and improving operational efficiencies.The decision to expand operations comes on the heels of rising demand for both generic and specialty pharmaceuticals in the Asia-